



FINANCIAL RECOVERY STRATEGIES

Settlement Summary

Flonase

If you or your business purchased Flonase nasal spray on or after May 19, 2004, a class action settlement may affect you.

DIRECT SETTLEMENT FUND: \$150 Million

Direct Covered Period: May 19, 2004 through March 6, 2006

Direct Filing Deadline: To Be Determined

INDIRECT SETTLEMENT FUND: \$35 Million

Indirect Covered Period: May 19, 2004 through March 31, 2009

Indirect Filing Deadline: August 15, 2013

Eligible Class Members: This notice applies to all persons and/or entities that purchased Flonase nasal spray (hereafter "Flonase" and defined below) in the United States and its territories: 1) directly from SmithKline Beecham Corporation (doing business as GlaxoSmithKline Inc.) or any of its predecessors or affiliates (hereafter the "Defendant" or "GSK") between May 19, 2004 and March 6, 2006; 2) indirectly from GSK for personal, family or household consumption between May 19, 2004 and March 31, 2009; or 3) to those Third-Party Payors ("TPPs" as defined below) who purchased, paid for, administered and/or reimbursed for Flonase nasal spray or generic Flonase for consumption by their members, employees, plan participants, beneficiaries or insureds between May 19, 2004 and March 31, 2009. Consumers are considered to have purchased and/or paid for Flonase or generic Flonase if they were either: (a) an uninsured consumer who paid the entire cost of the prescription; or (b) an insured consumer who made a co-payment or other partial out-of-pocket payment, or paid the entire cost because they had not met a deductible amount or had exceeded a benefit cap under their health plan or the cost was not otherwise covered under their health plan.

Case History: Several class action lawsuits were filed on behalf of direct and indirect purchasers in the Eastern District of Pennsylvania before Judge Brody alleging that GSK violated federal antitrust laws by wrongfully delaying the introduction of generic versions of the prescription drug Flonase into the United States market. The lawsuits were certified by Judge Brody to proceed as each respective class action and consolidated complaints were subsequently filed. In November 2012, a settlement was reached amongst the direct class and GSK in the amount of \$150 million. This settlement has been granted final approval by the Court. A settlement was also reached between the indirect class and GSK in the amount of \$35 million in December 2012. Final approval of this settlement is currently pending.

Note: A group of TPPs called the Settling Health Plans ("SHPs") are excluded from the indirect purchaser class as they settled with GSK for \$11 million under a separate agreement. These SHPs might receive payments from or contribute to the indirect settlement fund depending on the SHPs' pro rata share of Flonase purchases.

Definition of Third-Party Payor: TPPs include all health insurance companies, healthcare benefit providers, health maintenance organizations, self-funded health and welfare plans, and any other health benefit provider and/or entity that contracts with a health insurer acting as a third party administrator to administer their prescription drug benefits. TPPs include such entities that may provide prescription drug benefits for current or former public employees and/or retirees, but only to the extent that such entity was at risk for the cost of the payment(s).

Definition of Flonase: Flonase is a brand name prescription drug manufactured, marketed and sold by GSK. The generic name for Flonase is fluticasone propionate and it is a corticosteroid nasal spray used for treatment of nasal symptoms of seasonal and year-round allergies, as well as non-allergic rhinitis in adults and pediatric patients four years of age and older. It is non-habit forming and does not cause drowsiness.

Next Step: Once you execute and return our service agreement, we will provide immediate advice on the limited, specific documentation which should be preserved to support/enhance your future claim.

The Services Provided to Our Clients Include: FRS will work within your guidelines to enhance your claim value. We will review data and documentation for settlement eligibility and minimize any burden on your internal resources. FRS will prepare and file the claim forms with supporting documentation, including verifying and cataloging information into concise schedules. FRS will locate independent sources for your required data, and, if not available, will identify the easiest way for your organization to produce the data. If data is not available we will negotiate acceptable alternatives with the claims administrator. FRS will provide advice on any rule changes agreed to as part of the settlement. We monitor the progress of the settlement and provide periodic updates and are always available to answer all questions. When the settlement is complete we will verify accurate distribution amounts, take steps to correct underpayments and provide a detailed accounting of the claim. In addition, FRS will always identify new settlement and recovery opportunities that will be sent directly to you.

To learn more visit:

www.financialrecoverystrategies.com